# A Phase Ib/II open label, multi-arm, dose finding and expansion study of a novel thymidylate synthase inhibitor with immune modulating properties, NUC-3373, in combination with pembrolizumab or docetaxel in patients with advanced solid tumors (NuTide:303)

Gary Middleton<sup>1</sup>, James Spicer<sup>2</sup>, Burak Aktas<sup>2</sup>, Habana Dinizulu<sup>3</sup>, Richard H Wilson<sup>4</sup>, David J Harrison<sup>5,6</sup>, Elisabeth Oelmann<sup>6</sup>, Jeff Bloss<sup>6</sup>, Fiona Thistlethwaite<sup>3,7</sup>

- 1) Birmingham NHS Foundation Trust/University of Birmingham, UK
- 2) King's College London, Guy's Hospital, London, UK
- 3) The Christie NHS Foundation Trust
- 4) Beatson West of Scotland Cancer Centre/University of Glasgow, UK
- 5) University of St Andrews, UK
- 6) NuCana plc
- 7) University of Manchester, UK

### Abstract

#### Background

NUC-3373 is a novel thymidylate synthase (TS) inhibitor designed to directly deliver the active anti-cancer metabolite fluorodeoxyuridine-monophosphate (FUDR-MP or FdUMP) intracellularly. In addition to being a potent TS inhibitor, NUC-3373 has also been shown to cause DNA damage and promote the release of damage-associated molecular patterns. These diverse mechanisms position NUC 3373 as a potentially effective combination partner for several other anti-cancer agents.

#### Methods

NuTide:303 is a Phase Ib/II open label, multi-arm, parallel cohort dose-finding and expansion study designed to evaluate optimal combination partners for NUC-3373. Module 1 planned to enroll up to 12 evaluable patients with advanced/metastatic solid tumors to determine the recommended dose for NUC-3373 in combination with leucovorin (LV) and pembrolizumab. Module 2 planned to enroll approximately 6-12 evaluable patients with advanced/metastatic non-small cell lung cancer (of any histology) or pleural mesothelioma to determine the recommended dose for NUC-3373 in combination with LV and docetaxel. A 3+3 dose escalation design was used in both modules, with safety parameters continually assessed and tumor assessments conducted at screening and every 8 weeks from C1D1 until progression.

#### Results

Thirteen patients were enrolled in Module 1, with 9 evaluable for response. No DLTs were observed in these heavily pre-treated PD-(L)1 experienced patients with a variety of different tumor types. Four patients remained on treatment for >3 months and 3 patients were ongoing at the time of data cut-off. An objective response rate of 22% and a disease control rate of 67%

were reported. NUC-3373 + LV + pembrolizumab was well tolerated, the most common treatment-related adverse events (AEs) were nausea, vomiting, and diarrhea and the majority of events were Grade 1 (100%) or 2 (85%). Four patients were enrolled in Module 2, with 3 evaluable for response. Two patients treated at the first dose level achieved stable disease and completed >6 months of treatment The most common treatment-related AEs were fatigue (n=4) and diarrhea (n=3) and the majority of events were Grade 1 (100%) or 2 (100%).

#### Conclusions

Preliminary results from Module 1 show signals of anti-cancer activity and tolerability, providing support for further exploration of this combination in the Phase II part of the study. Preliminary results from Module 2 suggest that the probability of being able to escalate to typical efficacious doses of docetaxel used in combination is low due to overlapping toxicity. Further modifications to include the use of a different taxane in this combination are currently being considered.

## **Supplementary Data**

### **Table of Contents**

| Definition of DLT   | . 3 |
|---------------------|-----|
| Summary of Patients | .4  |

## **Definition of DLT**

DLT was defined as any of the following occurring during Cycle 1 (Module 1) or Cycles 1 and 2 (Module 2) that were not due to the protocol disease indication or to a known concurrent medical condition and were judged as clinically significant and related to study treatment.

| For dose escalation, DLTs were defined as follows   |  |  |  |
|---|--|--|--|
| Any Grade 4 AEs, with the exception of:   |  |  |  |
| Neutropenia lasting <72 hours that is not associated with fever or other clinical symptoms  |  |  |  |
| Lymphopenia   |  |  |  |
| Electrolyte abnormalities that are not associated with clinical sequelae and are corrected with appropriate management or supplementation within 72 hours of the onset                                      |  |  |  |
| Any Grade 3 AEs, with the exception of:   |  |  |  |
| Nausea and vomiting persisting for <2 days after optimal anti-emetic therapy  |  |  |  |
| Thrombocytopenia without significant bleeding (including platelet transfusions)   |  |  |  |
| Diarrhea persisting for <2 days after optimal anti-diarrheal treatment  |  |  |  |
| Hypertension persisting <7 days after treatment   |  |  |  |
| Infection or fever in the absence of neutropenia persisting <5 days   |  |  |  |
| Rash or photosensitivity persisting <7 days after treatment   |  |  |  |
| Fatigue persisting <7 days  |  |  |  |
| Liver function test elevations (AST/ALT) persisting <7 days after treatment with corticosteroids  |  |  |  |
| Immune-related adverse events persisting <7 days after treatment with corticosteroids   |  |  |  |
| Alopecia  |  |  |  |
| The following Grade 2 AEs were to be adjudicated as DLTs:   |  |  |  |
| Total bilirubin CTCAE v5 ≥Grade 2 with simultaneous ALT/AST CTCAE v5 ≥Grade 2   |  |  |  |
| Pneumonitis persisting >7 days despite treatment with corticosteroids   |  |  |  |
| Eye pain or reduction of visual acuity that does not respond to topical therapy and does not improve to Grade 1 severity within 2 weeks of the initiation of topical therapy OR requires systemic treatment |  |  |  |
| Other clinically significant toxicities (cardiotoxicity, neurotoxicity) including a single event or multiple occurrences of the same event that lead to a dosing delay of >7 days in Cycle 1                |  |  |  |

## **Summary of Patients**

| Module 1                               |  |   |  |
|--|--|---|--|
| Disease                                | Prior Treatment for<br>Metastatic Disease  | Metastatic<br>Sites                       |  |
| NSCLC<br>(squamous)                    | 1. docetaxel   | 1 x lung                                  |  |
| Sinonasal Carcinoma                    | 0  | 1 x nose                                  |  |
| Pleural Mesothelioma                   | 1. ipilimumab + nivolumab  | 2 x pleura                                |  |
| Urothelial Bladder                     | <ol> <li>gemcitabine + cisplatin</li> <li>avelumab</li> </ol>                    | 2 x liver                                 |  |
| Oropharyngeal<br>(p16+)                | <ol> <li>nivolumab</li> <li>investigational agent +<br/>atezolizumab</li> </ol>  | 2 x lung<br>1 x mediastinum<br>2 x pelvis |  |
| Oropharyngeal                          | 1. nivolumab   | 2 x lung<br>1 x mediastinum               |  |
| Urothelial Bladder<br>(Lynch Syndrome) | 1. atezolizumab  | 1 x lung                                  |  |
| Cutaneous Melanoma                     | <ol> <li>pembrolizumab</li> <li>dabrafenib + trametinib</li> </ol>               | 1 x lymph node                            |  |
| Cutaneous Melanoma                     | 1. ipilimumab + nivolumab  | 1 x lung<br>1 x liver<br>1 x mediastinum  |  |
| Pancreatic Adenocarcinoma              | <ol> <li>FOLFIRINOX</li> <li>gemcitabine + cisplatin</li> </ol>                  | 2 x liver                                 |  |
| Anal<br>(squamous)                     | <ol> <li>paclitaxel + carboplatin</li> <li>capecitabine + mitomycin c</li> </ol> | 2 x lung<br>1 x lymph node                |  |
| NSCLC<br>(squamous)                    | 1. pembrolizumab   | 2 x lymph node<br>2 x lung                |  |
| Cutaneous Melanoma                     | 1. ipilimumab + nivolumab  | 1 x lymph node                            |  |

| Module 2                |   |  |  |  |
|-------------------------|---|--|--|--|
| Disease                 | Prior Treatment for<br>Metastatic Disease   | Metastatic<br>Sites                                  |  |  |
| NSCLC<br>(squamous)     | 1. carboplatin + paclitaxel + pembrolizumab   | 1 x lung   |  |  |
| NSCLC<br>(non-squamous) | <ol> <li>pembrolizumab</li> <li>carboplatin + pemetrexed</li> </ol>                             | 2 x non-lymph node                                   |  |  |
| Pleural Mesothelioma    | <ol> <li>cisplatin + pemetrexed</li> <li>nivolumab</li> <li>carboplatin + pemetrexed</li> </ol> | 2 x lymph node<br>2 x mediastinum                    |  |  |
| NSCLC<br>(non-squamous) | <ol> <li>gemcitabine + cisplatin</li> <li>atezolizumab</li> </ol>                               | 1 x lung<br>2 x lymph node<br>1 x muscle/soft tissue |  |  |